Table 2 Characteristics of 232 NSCLC patients and with chi-square test for categorical variables
Characteristics | WBRT (n = 84) | Local Radiotherapy (n = 65) | WBRT + Boost (n = 83) | P value |
|---|---|---|---|---|
Age, years | 53(28–77) | 56(38–81) | 53(33–78) |  |
 > 60 | 21(25.0) | 24(36.9) | 23(27.7) | 0.263 |
 ≤ 60 | 63(75.0) | 41(63.1) | 60(72.3) |  |
Sex | ||||
 Female | 51(60.7) | 43(66.2) | 55(66.3) | 0.703 |
 Male | 33(39.3) | 22(33.8) | 28(33.7) |  |
Smoking status | ||||
 Never | 61(72.6) | 48(73.8) | 73(88.0) | 0.031 |
 Former/current | 23(27.4) | 17(26.2) | 10(12.0) |  |
EGFR mutation | ||||
 Exon 18 | 1(1.2) | 0 | 2(2.4) | 0.462 |
 Exon 19 | 36(42.9) | 24(36.9) | 36(43.4) |  |
 Exon 21 | 41(48.8) | 38(58.5) | 36(43.4) |  |
 Unclear | 6(7.1) | 3(4.6) | 9(10.8) |  |
Systemic therapy | ||||
 First-line EGFR TKIs | 38(45.2) | 30(46.2) | 40(48.2) | 0.927 |
 Second-line EGFR TKIs | 46(54.8) | 35(53.8) | 43(51.8) |  |
Lung-molGPA | ||||
 1–2 | 56(66.6) | 19(29.2) | 28(33.7) |  < 0.001 |
 2.5–3 | 24(28.6) | 33(50.8) | 41(49.4) |  |
 3.5–4 | 2(2.4) | 12(18.5) | 13(15.7) |  |
 Unclear | 2(2.4) | 1(1.5) | 1(1.2) |  |
Brain metastatic time | ||||
 Initial treatment | 47(56.0) | 41(63.1) | 56(67.5) | 0.303 |
 In the course of treatment | 37(44.0) | 24(36.9) | 27(32.5) |  |